REG - Haleon PLC - Historic Proforma Category Financial Performance

HALEONAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250707:nRSG9602Pa&default-theme=true

RNS Number : 9602P  Haleon PLC  07 July 2025

 

 

 

Haleon plc: Historic Proforma Category Financial Performance

7 July 2025: Haleon plc (the "Company" or "Haleon") today releases the
historical proforma category financial information, aligned with the
announcement at the Capital Markets Day on 1 May 2025. Haleon will now be
reporting six categories: Oral Health; Vitamins, Minerals, and Supplements
(VMS); Pain Relief; Respiratory Health; Digestive Health; and Therapeutic Skin
Health and Other.

Compared to previous reporting, the new structure:

 ●    Splits out Digestive Health & Other into Digestive Health, and Therapeutic
      Skin Health and Other
 ●    Smokers Health which had previously been reported as part of Digestive Health
      and Other will now be included in Respiratory Health
 ●    There are no changes to other categories not outlined above

      ( )

We will begin reporting in this new category structure at our 2025 Half Year
Results on 31 July 2025. The purpose of this change is to better align
Haleon's reporting with the strategic opportunities ahead as well as improve
visibility of Haleon's financial performance. Haleon's geographical split
remains unchanged.

Detailed below is the quarterly pro-forma actual and comparative financial
information on this basis. Definitions for non-IFRS measures can be found on
pages 19-27 in Haleon's 2024 Full Year Results, and pages 43-50 in Haleon's
Annual Report and Form 20-F 2024.

 Restated FY 2023 and FY 2024 reported revenue, organic revenue growth, and
 reported revenue growth by category (unaudited)
                                    2023                                                              2024
                                    £m revenue   Organic Revenue Growth  Reported Revenue Growth      £m revenue   Organic Revenue Growth  Reported Revenue Growth
 Oral Health                        3,136        10.6%                   6.1%                         3,312        9.6%                    5.6%
 VMS                                1,640        0.9%                    -2.1%                        1,696        7.6%                    3.4%
 Pain Relief                        2,652        7.4%                    4.0%                         2,564        0.1%                    -3.3%
 Respiratory Health                 2,244        11.7%                   8.2%                         2,122        1.0%                    -5.4%
 Digestive Health                   1,012        5.8%                    1.9%                         1,029        5.5%                    1.7%
 Therapeutic Skin Health and Other  618          8.8%                    1.5%                         510          9.8%                    -17.5%
 TOTAL                              11,302       8.0%                    4.1%                         11,233       5.0%                    -0.6%

 

 Restated quarterly reported revenue by category (unaudited)
                                    2023                                                                2024                                                                2025
 £m                                 Q1          Q2          Q3          Q4          FY                  Q1          Q2          Q3          Q4          FY                  Q1
 Oral Health                            811         778         790         757        3,136                854         829         810         819        3,312                880
 VMS                                    405         411         410         414        1,640                422         435         407         432        1,696                416
 Pain Relief                            724         681         636         611        2,652                662         641         628         633        2,564                661
 Respiratory Health                     638         455         563         588        2,244                590         454         581         497        2,122                525
 Digestive Health                       259         256         234         263        1,012                256         264         239         270        1,029                254
 Therapeutic Skin Health and Other      149         171         165         133           618               135         152         115         108           510               117
 TOTAL                               2,986       2,752       2,798       2,766       11,302              2,919       2,775       2,780       2,759       11,233              2,853

 

 Restated quarterly organic revenue growth by category (unaudited)
                                    2023                    2024                                                      2025
 %                                  FY                      Q1          Q2          Q3          Q4          FY        Q1
 Oral Health                        10.6%                   10.6%       9.1%        8.2%        10.6%       9.6%      6.6%
 VMS                                0.9%                    9.9%        8.5%        3.7%        8.2%        7.6%      0.9%
 Pain Relief                        7.4%                    -4.8%       -4.0%       3.1%        7.4%        0.1%      2.6%
 Respiratory Health                 11.7%                   -2.7%       1.3%        8.2%        -2.6%       1.0%      0.7%
 Digestive Health                   5.8%                    2.2%        5.2%        9.0%        5.8%        5.5%      2.3%
 Therapeutic Skin Health and Other  8.8%                    7.4%        10.7%       0.7%        24.2%       9.8%      10.4%
 TOTAL                              8.0%                    3.0%        4.1%        6.1%        6.8%        5.0%      3.5%

 

 Restated quarterly reported revenue growth by category (unaudited)
                                    2023                        2024                                                          2025
 %                                  FY                          Q1            Q2            Q3            Q4      FY          Q1
 Oral Health                        6.1%                        5.3%          6.6%          2.5%          8.2%    5.6%        3.0%
 VMS                                -2.1%                       4.2%          5.8%          -0.7%         4.3%    3.4%        -1.4%
 Pain Relief                        4.0%                        -8.6%         -5.9%         -1.3%         3.6%    -3.3%       -0.2%
 Respiratory Health                 8.2%                        -7.5%         -0.2%         3.2%          -15.5%  -5.4%       -11.0%
 Digestive Health                   1.9%                        -1.2%         3.1%          2.1%          2.7%    1.7%        -0.8%
 Therapeutic Skin Health and Other  1.5%                        -9.4%         -11.1%        -30.3%        -18.8%  -17.5%      -13.3%
 TOTAL                              4.1%                        -2.2%         0.8%          -0.6%         -0.3%   -0.6%       -2.3%

 

 

Enquiries

 

 Investors                                                                       Media

 Jo Russell                              +44 7787 392441                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Victoria Durman                      +44 7894 505730
 Emma White                              +44 7823 523562
 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans six major categories - Oral Health, Vitamins, Minerals and Supplements
(VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin
Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUPUGCMUPAPGQ